Early stroke after left ventricular assist device implantation: role of right heart failure

Ilkun Park[1]^, Jeong Hoon Yang[2], Darae Kim[2], Jin-Oh Choi[2], Eun-Seok Jeon[2], Kiick Sung[1]^, Wook Sung Kim[1]^, Yang Hyun Cho[1]^

[1]Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkman University School of Medicine, Seoul, Korea;
[2]Division of Cardiology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University College of Medicine, Seoul, Korea

Contributions: (I) Conception and design: I Park, YH Cho, K Sung, WS Kim; (II) Administrative support: YH Cho; (III) Provision of study materials or patients: I Park, YH Cho, JH Yang, D Kim, JO Choi, ES Jeon, K Sung, WS Kim; (IV) Collection and assembly of data: I Park, YH Cho; (V) Data analysis and interpretation: I Park, YH Cho; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Yang Hyun Cho, MD, PhD. Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea. Email: mdcho95@gmail.com.

Background: Both stroke and right heart failure (RHF) are common and serious complications after left ventricular assist device (LVAD) implantation. The objective of this study was to evaluate relation between stroke and RHF early after LVAD implantation.

Methods: This is a retrospective observational cohort study. From January 2012 to December 2020, patients who underwent LVAD implantation in a single-center were enrolled. Patients with a non-dischargeable LVAD or without follow-up data were excluded. Early stroke was defined as a stroke event within 6 months after implantation. Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) definition was used for the diagnosis of RHF.

Results: A total of 70 patients underwent LVAD implantation. Sixty-seven patients (95.7%) were successfully discharged and 16 patients (22.9%) died during follow-up. 14 patients (20.0%) experienced a stroke within 6 months after implantation, and 0.28 stroke events per patient-year occurred during follow-up. Postoperative RHF was more common in the stroke group (64.3% *vs.* 23.2%, P=0.008) and the median time from implantation to RHF was 1 day. In the Cox multivariable analysis, postoperative RHF [hazard ratio (HR): 5.063; 95% confidence interval (CI): 1.682–15.245; P=0.004], and cerebral perfusion pressure (CPP) on postoperative day (POD) 1 (HR: 0.923; 95% CI: 0.858–0.992; P=0.030) were independent predictors for early stroke. A CPP of 62 mmHg (sensitivity, 71.4%; specificity, 59.3%) was the cutoff value for early stroke according to the receiver operating characteristic (ROC) analysis.

Conclusions: RHF after LVAD implantation may be a risk factor for early stroke. Prevention and management of postoperative RHF with adequate CPP could prevent early stroke after LVAD implantation.

Keywords: Left ventricular assist device (LVAD); postoperative stroke; right heart failure (RHF); early stroke; mechanical circulatory support

---

^ ORCID: Ilkun Park, 0000-0001-6005-640X; Kiick Sung, 0000-0003-0768-9587; Wook Sung Kim, 0000-0001-7808-3385; Yang Hyun Cho, 0000-0003-1685-3641.

Introduction

Left ventricular assist devices (LVADs) are increasingly used to treat end-stage heart failure. LVADs extend survival and improved quality of life in heart failure patients (1). However, post-LVAD stroke is a frequent and devastating complication (2). The incidence of stroke after LVAD implantation exhibits a bimodal reverse J-shaped curve, with risk peaking immediately after implantation and increasing again 1 year later (3,4), indicating both early and late post-LVAD stroke phases.

Until now, maintaining adequate blood pressure (5,6) and anticoagulation targets (5,7) and preventing complications related to post-LVAD maintenance, including post-LVAD infection (8) and pump thrombosis (3), have been investigated as prognostic factors for post-LVAD stroke. However, few studies have analyzed early-phase and late-phase stroke separately (3,9,10). Postoperative right heart failure (RHF) is also a fatal complication after LVAD implantation (11). Patients with RHF typically have increased central venous pressure (CVP) and decreased mean arterial pressure (MAP). This physiology can reduce cerebral perfusion pressure (CPP) which causes cerebral hypoperfusion and congestion. Herein, we investigated the relation between early stroke and postoperative RHF. We present this article in accordance with the STROBE reporting checklist (available at https://jtd.amegroups.com/article/view/10.21037/jtd-23-1194/rc).

Highlight box

Key findings
- Right heart failure (RHF) after left ventricular assist device (LVAD) implantation was a risk factor for early post-LVAD stroke.

What is known and what is new?
- The incidence of stroke after LVAD implantation exhibits a bimodal reverse J-shaped curve, indicating both early and late post-LVAD stroke phases.
- Postoperative RHF might have significant impact on early stroke.

What is the implication, and what should change now?
- Since postoperative RHF usually accompanies low cerebral perfusion pressure (CPP) and can cause watershed infarct or lacunar infarct, it is suggested that maintaining mean CPP at least 60 mmHg or higher immediately after LVAD implantation could help reduce early stroke after LVAD implantation. This could be a new approach different from the current trend focusing on the risk of high mean blood pressure after LVAD implantation.

Methods

This was a single-center retrospective observational study. From January 2012 to December 2020, patients who underwent LVAD implantation in our medical center were eligible for study inclusion (*Figure 1*). We excluded patients with non-dischargeable LVAD insertion and one foreign patient lost to follow-up because she returned to her home country after implantation. The follow-up completion rate was 100%. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The Institutional Review Board of Samsung Medical Center approved this study (SMC 2021-09-016-001, date of approval: September 8, 2021). The Institutional Review Board waived informed consent from individual patients because this retrospective study had minimal risk for patients.

Study variables and definitions

Early stroke was defined as stroke within 6 months after implantation. Stroke was diagnosed using a standard neurological examination performed by a neurologist and documented with appropriate diagnostic imaging, such as computed tomography. Transient ischemic attacks were also included as stroke events. Patients who experienced strokes within 6 months of LVAD implantation were categorized into the stroke group; those who did not experience strokes in the first 6 months were categorized into the no-stroke group. The detailed definitions of post-LVAD complications including RHF, which are consistent with Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) definitions, are provided in the Supplementary materials online (12). Frailty was assessed by a specialist in rehabilitation medicine and was defined as category 4 or higher according to the Spirduso classification (13).

Warfarin use was calculated as the percentage of overall time in therapeutic range (TTR) using the Rosendaal method (14). CPP was defined as the difference between MAP and CVP (15), which were measured simultaneously by invasive monitoring.

Patient management during and after LVAD implantation

Transesophageal monitoring was routinely used to exclude interatrial shunt in the operating room. After

Figure 1 Study flow diagram. A total of 70 patients implanted with LVAD in a single center were enrolled. Stroke was defined as early stroke within 6 months of implantation. LVAD, left ventricular assist device.

LVAD implantation, the target MAP was between 70 and 90 mmHg. In patients who underwent HeartWare Ventricular Assist Device System (HVAD) implantation, target MAP was <80 mmHg. If the patient did not have an arterial line, blood pressure was measured with an automated non-invasive cuff in patients; in patients who fail to check blood pressure from a non-invasive cuff, manual measurement with Doppler ultrasound assistance was used. For anticoagulation, an intravenous heparin infusion was initiated 12 hours after LVAD implantation, targeting an activated partial thromboplastin time of 45–55 seconds until the international normalized ratio (INR) reached 1.5 if no significant post-LVAD bleeding occurred. Warfarin, targeting an INR of 2.0–3.0, and an antiplatelet agent was initiated the day after implantation.

Statistical analysis

The detailed statistical analysis process is provided in the Supplementary materials online. Categorical variables are reported as frequencies with percentages; continuous variables are reported as means with standard deviations or medians with range. The cumulative incidence of RHF is estimated by a Fine-Gray model which accounts for the competing risk of death and heart transplantation. A Cox proportional hazard regression analysis was performed to identify predictors of early stroke at 6 months after

implantation. Receiver operating characteristic (ROC) curve analysis for early stroke was performed, and the area under the curve (AUC) was calculated. To compare repetitive values of pump flow, mean blood pressure, INR, and lactate dehydrogenase (LDH) concentration according to stroke, we used a linear mixed model.

Results

Baseline characteristics

Among the 70 patients who were enrolled, 14 patients (20.0%) experienced a postoperative stroke during the 6 months after LVAD implantation (*Table 1*, *Figure 2A*). About 0.28 stroke events per patient-year occurred during follow-up. Mean age of the study population was 63.0±13.9 years and 55 patients (78.6%) were men. 24 patients (34.3%) received extracorporeal membrane oxygenation before LVAD implantation and 22 patients (31.4%) had history of cardiopulmonary resuscitation before LVAD implantation.

Patients with stroke were more likely to have preoperative frailty (92.9% *vs.* 57.1%, P=0.013) and cardiac surgery history (57.1% *vs.* 12.5%, P=0.001), compared to those without stroke. Specifically, a history of coronary artery bypass graft was more frequent in the stroke group compared with the frequency in the no-stroke group (42.9% *vs.* 5.4%, P=0.001) (Table S1).

Table 1 Clinical and echocardiographic characteristics 6 months after implantation

Variables	No-stroke group (n=56)	Stroke group (n=14)	P value
Age (years)	66.50 [56.50–73.25]	64.00 [59.00–69.25]	0.649
Male sex	45 (80.4)	10 (71.4)	0.480
Body mass index (kg/m^2)	23.26±3.00	23.28±3.31	0.982
Preoperative comorbidity			
Frailty	32 (57.1)	13 (92.9)	0.013
DM	32 (57.1)	9 (64.3)	0.856
HTN	26 (46.4)	8 (57.1)	0.676
Dialysis	21 (37.5)	6 (42.9)	0.951
Previous stroke history	10 (17.9)	5 (35.7)	0.275
Smoking history	27 (48.2)	8 (57.1)	0.765
Solid organ cancer	8 (14.3)	1 (7.1)	0.675
Liver dysfunction[†]	18 (32.1)	4 (28.6)	>0.99
Atrial fibrillation	32 (57.1)	8 (57.1)	>0.99
Cardiac surgery history	7 (12.5)	8 (57.1)	0.001
CPR history	18 (32.1)	4 (28.6)	>0.99
ECMO status before LVAD implantation	18 (32.1)	6 (42.9)	0.659
Ischemic etiology of heart failure	26 (46.4)	9 (64.3)	0.370
Medical support status			0.452
Bridge to transplantation	29 (51.8)	9 (64.3)	
Bridge to candidacy	3 (5.4)	1 (7.1)	
Destination therapy	24 (42.9)	4 (28.6)	
Preoperative ECHO			
LVEF			0.393
30–39%	6 (10.7)	3 (21.4)	
20–29%	30 (53.6)	5 (35.7)	
<20%	20 (35.7)	6 (42.9)	
LVEDD (cm)	6.87±1.10	6.88±0.96	>0.99
TR			0.739
None	2 (3.6)	1 (7.1)	
Mild	34 (60.7)	9 (64.3)	
Moderate	14 (25.0)	2 (14.3)	
Severe	8 (14.3)	3 (21.4)	
Mean PAP (mmHg)	35.40±11.16	37.55±9.20	0.558
CVP	11.0 [7.00–15.00]	10.00 [8.50–18.00]	0.670

Data are expressed as median [range], number (%), or mean ± standard deviation. [†], liver dysfunction was defined as liver cirrhosis or congestive hepatomegaly. DM, diabetes mellitus; HTN, hypertension; CPR, cardiopulmonary resuscitation; ECMO, extracorporeal membrane oxygenation; LVAD, left ventricular assist device; ECHO, echocardiography; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic diameter; TR, tricuspid regurgitation; PAP, pulmonary arterial pressure; CVP, central venous pressure.

Figure 2 Time to event curves for early stroke (A) in total patients and (B) according to RHF. Cumulative incidence functions and competing risk models were used considering death and heart transplantation as competing events. The colored shaded areas in both curves represent the 95% CI. RHF, right heart failure; CI, confidence interval.

Surgical and postoperative characteristics

During the study period, HeartMate II Left Ventricular Assist System (HMII), HVAD, and HeartMate 3 Left Ventricular Assist System (HM3) were implanted in 23 patients (32.9%), 46 patients (65.7%), and 1 patient (1.4%), respectively (*Table 2*). HVADs were more frequently implanted in the stroke group compared with the frequency in the no-stroke group (92.9% *vs.* 58.9%, P=0.042). Postoperative antiplatelet and heparin bridging were used in 56 patients (80.0%) and 57 patients (81.4%), respectively.

The frequencies of postoperative atrial fibrillation, postoperative antiplatelet use, heparin bridging to warfarin, and TTR <40% were similar between the groups. Mean CPP at postoperative day (POD) 1 (58.06 *vs.* 63.43 mmHg, P=0.026; *Table 2*, Figure S1) was lower in the stroke group compared with these parameters in the no-stroke group. Pump flow during the 7 days within implantation, MAP within 3 days of implantation, and CVP within 3 days of implantation were similar between the groups (*Table 2*, Figures S1,S2).

Postoperative outcomes and stroke

Sixty-seven patients (95.7%) were successfully discharged and 16 patients (22.9%) died during follow-up (*Table 3*). No significant differences in postoperative ventilator support, inotropic support, atrial fibrillation, and infection were detected between the two groups. However, postoperative RHF was more common in the stroke group (64.3% *vs.* 23.2%, P=0.008) and the median time from implantation to RHF was 1 day.

Among the 14 patients (20.0%), who experienced a postoperative stroke during the 6 months after LVAD implantation, five patients had ischemic strokes, one patient had posterior reversible encephalopathy syndrome, and eight patients had hemorrhagic strokes. Among the eight cases of hemorrhagic stroke, one was suspected to be a hemorrhagic transformation of an ischemic stroke, and another was due to trauma-induced stroke. The median modified Rankin scale at the stroke event was 2, and the median time from implantation to stroke was 47 days (range, 1–147 days). There were no statistical differences in the rates of all-cause death between patients with stroke and those without stroke (Figure S3).

Risk factors for early stroke

Patients with postoperative RHF had a significantly higher 6-month stroke rate than patients without postoperative RHF (44.6% *vs.* 10.5%, P=0.002; *Figure 2B*). In the multivariable analyses including RHF as a variable (Table S2, *Table 4*, *Figure 3*), preoperative frailty [hazard ratio (HR): 7.703; 95% confidence interval (CI): 1.001–59.279; P=0.049], preoperative cardiac surgery history (HR: 3.065; 95% CI: 1.059–8.869; P=0.039), and postoperative RHF (HR: 5.063; 95% CI: 1.682–15.245; P=0.004) were significant independent predictors of early stroke. In the multivariable analyses including CPP at POD 1 as a variable (Table S3, Figure S4), preoperative cardiac surgery history (HR: 3.916; 95% CI: 1.323–11.594; P=0.014), postoperative antiplatelet use (HR: 0.286; 95% CI: 0.093–0.881; P=0.029), and CPP at POD 1 (HR: 0.923; 95% CI: 0.858–0.992; P=0.030) were independent risk factors for early stroke. In the ROC curve and cutoff analyses using the Youden index

Table 2 Surgical and postoperative characteristics 6 months after implantation

Variables	No-stroke group (n=56)	Stroke group (n=14)	P value
Surgical characteristics			
Device type			0.042
HMII	22 (39.3)	1 (7.1)	
HM3	1 (1.8)	0 (0.0)	
HVAD	33 (58.9)	13 (92.9)	
Intracardiac thrombus removal	7 (12.5)	1 (7.1)	>0.99
Concomitant valve surgery	15 (26.8)	1 (7.1)	0.164
Postoperative characteristics			
Antiplatelet use	47 (83.9)	9 (64.3)	0.204
Heparin bridging	44 (78.6)	13 (92.9)	0.441
TTR using Rosendaal method <40%	34 (60.7)	7 (50.0)	0.564
Pump flow within 7 days of implantation (L/min)	4.11±0.98	3.98±0.64	0.621
Mean MAP within 3 days of implantation (mmHg)	74.32±7.36	71.05±6.79	0.136
Mean CVP within 3 days of implantation (mmHg)	10.26±2.38	11.04±2.35	0.279
Mean CPP within 3 days of implantation (mmHg)	63.99±8.24	60.45±8.11	0.154
Mean CPP at POD 0 (mmHg)	63.06±10.10	57.50±7.38	0.089
Mean CPP at POD 1 (mmHg)	63.43±7.79	58.06±8.28	0.026
Mean CPP at POD 2 (mmHg)	63.51±9.68	58.06±8.28	0.689
Mean CPP at POD 3 (mmHg)	65.46±8.45	61.46±10.69	0.191

Data are expressed as number (%) or mean ± standard deviation. HMII, HeartMate II Left Ventricular Assist System; HM3, HeartMate 3 Left Ventricular Assist System; HVAD, HeartWare Ventricular Assist Device System; TTR, time in therapeutic range; MAP, mean arterial pressure; CVP, central venous pressure; CPP, cerebral perfusion pressure; POD, postoperative day.

(Figure S5), the AUC for CPP was 0.688. The CPP cutoff value for predicting an early stroke event was 62 mmHg (sensitivity, 71.4%; specificity, 59.3%).

Patients with postoperative RHF

Patients in the RHF group were younger compared to patients in the no RHF group (56.68 *vs.* 65.94 years, P=0.009), but comorbidities and echocardiographic characteristics did not differ between the groups (Table S4). MAP was lower (69.20 *vs.* 73.97 mmHg, P<0.001), CVP was higher (11.82 *vs.* 9.85 mmHg, P<0.001), and mean CPP was lower (57.38 *vs.* 64.13 mmHg, P<0.001) within 3 days of implantation (*Figure 4*, Table S5) in the RHF group compared with these measurements in the no RHF group.

Patients who presented RHF after surgery received various forms of support during the early stage, including multiple inotropes (n=22, 100.0%; median duration of support, 7 days), inhaled nitric oxide (n=9, 40.9%; median duration of support, 2 days), continuous renal replacement therapy (n=15, 68.2%; median duration of support, 7.5 days), or right ventricular assist device support (n=4, 18.2%; median duration of support, 8.5 days; Table S6). Upon discharge, they continued to receive sildenafil (n=15, 68.2%), digoxin (n=8, 36.4%), and high-dose diuretics (n=4, 18.2%). After 6 months following LVAD surgery, 10 patients (45.5%), 3 patients (13.6%), and 4 patients (18.2%) were still on sildenafil, digoxin, and high-dose diuretics, respectively.

Discussion

Two main findings from this study are important: (I)

Table 3 Overall postoperative outcomes

Variables	No-stroke group (n=56)	Stroke group (n=14)	P value
Heart transplantation	24 (42.9)	5 (35.7)	0.856
Survival to discharge	55 (98.2)	12 (85.7)	0.858
ICU stay (days)	9.91±9.65	15.14±13.34	0.099
Hospital stay (days)	54.50±58.91	85.21±87.40	0.231
Postoperative inotropic support (days)	8.12±10.39	8.29±4.45	0.930
Postoperative ventilator support (days)	4.02±6.51	4.86±4.62	0.652
Postoperative CRRT support (days)	3.00±6.49	6.64±8.76	0.085
Postoperative atrial fibrillation	11 (19.6)	5 (35.7)	0.355
Postoperative infection	15 (26.8)	2 (14.3)	0.531
Postoperative pump thrombosis	0 (0.0)	0 (0.0)	NA
Heparin induced thrombocytopenia	0 (0.0)	0 (0.0)	NA
Postoperative RHF	13 (23.2)	9 (64.3)	0.008
Implantation to RHF (days)	1 [1–2]	1 [0.5–3.5]	0.948
CPC score at discharge			0.303
1	54 (96.4)	12 (85.7)	
2	1 (1.8)	1 (7.1)	
4	1 (1.8)	1 (7.1)	
Stroke			–
Ischemic stroke	–	5 (35.7)	
Hemorrhagic stroke	–	8 (57.1)	
Hemorrhagic transformation of ischemic stroke	–	1 (7.1)	
Traumatic	–	1 (7.1)	
PRES	–	1 (7.1)	
Modified Rankin scale at stroke event	–	2 [0–6]	
LVAD implantation to stroke (days)	–	47 [1–147]	

Data are expressed as number (%), mean ± SD, or median [range]. ICU, intensive care unit; CRRT, continuous renal replacement therapy; NA, not available; RHF, right heart failure; CPC, cerebral performance category; PRES, posterior reversible encephalopathy syndrome; LVAD, left ventricular assist device.

Table 4 Multivariable analysis for postoperative early stroke

Variables	Multivariable analysis		
	HR	95% CI	P value
Preoperative			
Frailty	7.703	1.001–59.279	0.049
Cardiac surgery history	3.065	1.059–8.869	0.039
Postoperative			
RHF	5.063	1.682–15.245	0.004

HR, hazard ratio; CI, confidence interval; RHF, right heart failure.

postoperative RHF is an independent risk factor for early stroke after LVAD implantation, and (II) low CPP, which occurred in patients with post-LVAD RHF, is an independent risk factor for early stroke in LVAD-implanted patients. Postoperative stroke is a frequent and devastating complication after LVAD implantation, and many studies focused on correctable and non-correctable risk factors for postoperative stroke. One notable investigation into the risk factors for neurologic events suggested that anticoagulation, antiplatelet therapy, and blood pressure

Figure 3 Forest plot based on the results of multivariable analysis of the factors associated with early stroke. The factors that were found to be significant (P<0.2) in univariable analysis were entered into a multivariable Cox regression model.


Figure 4 Serial changes in (A) CPP, (B) MAP, and (C) CVP according to RHF. The horizontal line in the middle of each box indicates the median; the top and bottom borders of the box mark the 75th and 25th percentiles, respectively; and the top and bottom ends of the line mark the 90th and 10th percentiles. CPP, cerebral perfusion pressure; MAP, mean arterial pressure; CVP, central venous pressure; RHF, right heart failure.

management affect the risk of cerebrovascular accidents after HVAD implantation (5,6). Other studies suggested that postoperative infection (8), low pump flow (3), anticoagulation (16), and etiology of heart failure (7) were risk factors for stroke. However, very few studies focused on risk factors for early stroke, except one study suggesting that low cardiac flow was a risk factor for early stroke (3) and a report showing a bimodal curve for the hazard function of stroke over time (4).

In this study, postoperative RHF was an independent risk factor for early stroke after LVAD implantation. Postoperative RHF is a common and harmful complication

after LVAD implantation (11) and RHF usually occurs in the first 2 weeks (17). Heart failure is a well-known risk factor for stroke in the general population (18-20). In a population-based cohort study, the risk of stroke was strongly increased shortly after the diagnosis of heart failure but returned to normal within 6 months after the onset of heart failure (18), which was the period for early stroke in our study. RHF in LVAD-implanted patients may increase the risk of stroke similar to heart failure in the general population.

Two possible mechanisms might account for the association between RHF and stroke in LVAD-implanted

patients: thromboembolism and hypoperfusion (20). Coagulopathy and stasis of blood flow in akinetic ventricular segments and dilated atrium in RHF might increase thrombus formation (20). This mechanism also explains the effects of preoperative cardiac surgery history on stroke development in this study; thrombogenicity is increased by artificial valve materials and akinetic ventricular segments after coronary artery bypass grafting surgery. However, we did not detect any differences in the anticoagulation profiles (i.e., postoperative antiplatelet use, heparin bridging, TTR, etc.) or postoperative LDH levels indicative of thrombosis (21,22) between the stroke and the non-stroke groups.

Regarding hypoperfusion, the CPP and cerebrovascular resistance regulate cerebral blood flow (15). Although cerebral autoregulation maintains cerebral blood flow at a relatively constant level over a wide range of CPP (50 to 100 mmHg) (15,23), autoregulation of cerebrovascular resistance might be dysfunctional in certain circumstances [i.e., chronic hypertension (16,24), cardiac arrest (23), chronic heart failure (24), continuous flow LVAD (25)] that are frequently observed in this study population, and minor changes of CPP could injure the brain (19,20). During cerebral hypoperfusion in patients with post-LVAD RHF, deep brain structures that are supplied by the deep penetrating arteries and lack collateral flow or structures located at the junction supplied by both the middle and anterior cerebral arteries may be vulnerable to ischemic damage (19,20). Furthermore, in a state where autoregulation is compromised, if CVP increases due to RHF, this can potentially lead to hemorrhagic strokes caused by venous or capillary rupture and could also serve as a cause for posterior reversible encephalopathy syndrome.

Interestingly, our results suggest that low perfusion pressure is a warning sign for the development of early stroke. In our study cohort, CPP was significantly lower in patients with post-LVAD RHF compared with CPP in patients without RHF on the first 3 PODs. The low cerebral perfusion on POD 1 was an independent risk factor for developing stroke, with a cutoff value of 62 mmHg. Previous studies focused on high MAP as a risk factor for developing stroke in LVAD-implanted patients (5,6). However, this study suggests that, during the early phase after LVAD implantation, when cerebral autoregulation might be dysfunctional or right-shifted (26), low CPP might increase the risk of stroke and should be avoided. We recommend that CPP should not be lower than 60 mmHg in the immediate postoperative period after LVAD implantation, which is consistent in other recommendations

in post-cardiac arrest care or in traumatic brain injury (27). Target CPP in the early postoperative period of LVAD implantation need to be investigated in future large-scale studies.

Several limitations of this study should be mentioned. Firstly, this is a retrospective single-center study with a small number of subjects, and selection bias could exist. Secondly, one limitation of this study is the inclusion of various LVAD devices, such as HMII, HM3, and HVAD. Although HVAD is no longer in use due to poor hemocompatibility, a significant number of patients still receive HVAD support. Therefore, insights from the older devices remain relevant. Furthermore, in this study, the influence of device type was accounted for in the Cox multivariable analysis, and since the focus is on the association between RHF and stroke, there are sufficient implications for the HM3 currently in use also. Future investigations should explore the association between stroke and RHF specifically in the context of the commonly used HM3 device. Thirdly, there are inherent limitations in establishing a causal relationship between RHF and stroke. It is challenging to determine the prolonged effect of RHF on post-LVAD hemodynamics (Table S6), making it difficult to distinguish the extent to which RHF contributes to individual stroke events. However, this study serves as an initial exploration of the link between RHF and stroke, and its significance lies in paving the way for further comprehensive investigations. In-depth research that thoroughly examines the impact of RHF and associated parameters on post-LVAD stroke is crucial for elucidating a causal relationship in the future. Lastly, ischemic and hemorrhagic stroke were not analyzed separately. Nevertheless, in fact, hemorrhagic stroke and ischemic stroke are known to share risk factors including infection, female sex, hypertension, and antiplatelet use. In addition, in the real world, it is hard to differentiate hemorrhagic stroke from hemorrhagic conversion of ischemic stroke. Future large-scale studies might be needed to differentiate the effects of RHF and CPP on the two types of strokes.

Conclusions

Post-LVAD RHF is a risk factor for early stroke after LVAD implantation, especially in those with dysfunctional cerebral autoregulation and low CPP. Prevention of RHF by appropriate patient selection and management of RHF with adequate CPP may reduce the incidence of post-LVAD stroke.

Acknowledgments

Footnote

Reporting Checklist: The authors have completed the STROBE reporting checklist. Available at https://jtd.amegroups.com/article/view/10.21037/jtd-23-1194/rc

Data Sharing Statement: Available at https://jtd.amegroups.com/article/view/10.21037/jtd-23-1194/dss

Peer Review File: Available at https://jtd.amegroups.com/article/view/10.21037/jtd-23-1194/prf

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-23-1194/coif). Y.H.C. reports that this work was supported by the Korea Medical Device Development Fund grant funded by the Korea government (the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, the Ministry of Health & Welfare, the Ministry of Food and Drug Safety) (Project Number: RS-2020-KD000159). The other authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The Institutional Review Board of Samsung Medical Center approved this study (SMC 2021-09-016-001, date of approval: September 8, 2021). The Institutional Review Board waived informed consent from individual patients because this retrospective study had minimal risk for patients.

References

1. Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 2009;361:2241-51.
2. Acharya D, Loyaga-Rendon R, Morgan CJ, et al. INTERMACS Analysis of Stroke During Support With Continuous-Flow Left Ventricular Assist Devices: Risk Factors and Outcomes. JACC Heart Fail 2017;5:703-11.
3. Samura T, Yoshioka D, Toda K, et al. Risk of stroke early after implantation of a left ventricular assist device. J Thorac Cardiovasc Surg 2019;157:259-267.e1.
4. Frontera JA, Starling R, Cho SM, et al. Risk factors, mortality, and timing of ischemic and hemorrhagic stroke with left ventricular assist devices. J Heart Lung Transplant 2017;36:673-83.
5. Teuteberg JJ, Slaughter MS, Rogers JG, et al. The HVAD Left Ventricular Assist Device: Risk Factors for Neurological Events and Risk Mitigation Strategies. JACC Heart Fail 2015;3:818-28.
6. Milano CA, Rogers JG, Tatooles AJ, et al. HVAD: The ENDURANCE Supplemental Trial. JACC Heart Fail 2018;6:792-802.
7. Boyle AJ, Jorde UP, Sun B, et al. Pre-operative risk factors of bleeding and stroke during left ventricular assist device support: an analysis of more than 900 HeartMate II outpatients. J Am Coll Cardiol 2014;63:880-8.
8. Cho SM, Moazami N, Katz S, et al. Stroke Risk Following Infection in Patients with Continuous-Flow Left Ventricular Assist Device. Neurocrit Care 2019;31:72-80.
9. Yoshioka D, Sakaniwa R, Toda K, et al. Relationship Between Bacteremia and Hemorrhagic Stroke in Patients With Continuous-Flow Left Ventricular Assist Device. Circ J 2018;82:448-56.
10. Yoshioka D, Okazaki S, Toda K, et al. Prevalence of Cerebral Microbleeds in Patients With Continuous-Flow Left Ventricular Assist Devices. J Am Heart Assoc 2017;6:e005955.
11. LaRue SJ, Raymer DS, Pierce BR, et al. Clinical outcomes associated with INTERMACS-defined right heart failure after left ventricular assist device implantation. J Heart Lung Transplant 2017;36:475-7.

12. Interagency Registry for Mechanically Assisted Circulatory Support. Appendix D - Adverse Event Definitions. Accessed December 13, 2023. Available online: http://classic.clinicaltrials.gov/ProvidedDocs/42/NCT02268942/Prot_000.pdf

13. Freiberger E, Häberle L, Spirduso WW, et al. Long-term effects of three multicomponent exercise interventions on physical performance and fall-related psychological outcomes in community-dwelling older adults: a randomized controlled trial. J Am Geriatr Soc 2012;60:437-46.

14. Rosendaal FR, Cannegieter SC, van der Meer FJ, et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993;69:236-9.

15. Markus HS. Cerebral perfusion and stroke. J Neurol Neurosurg Psychiatry 2004;75:353-61.

16. Harvey L, Holley C, Roy SS, et al. Stroke After Left Ventricular Assist Device Implantation: Outcomes in the Continuous-Flow Era. Ann Thorac Surg 2015;100:535-41.

17. Kormos RL, Teuteberg JJ, Pagani FD, et al. Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: incidence, risk factors, and effect on outcomes. J Thorac Cardiovasc Surg 2010;139:1316-24.

18. Alberts VP, Bos MJ, Koudstaal P, et al. Heart failure and the risk of stroke: the Rotterdam Study. Eur J Epidemiol 2010;25:807-12.

19. Havakuk O, King KS, Grazette L, et al. Heart Failure-Induced Brain Injury. J Am Coll Cardiol 2017;69:1609-16.

20. Kim W, Kim EJ. Heart Failure as a Risk Factor for Stroke. J Stroke 2018;20:33-45.

21. Cowger JA, Romano MA, Shah P, et al. Hemolysis: a harbinger of adverse outcome after left ventricular assist device implant. J Heart Lung Transplant 2014;33:35-43.

22. Uriel N, Morrison KA, Garan AR, et al. Development of a novel echocardiography ramp test for speed optimization and diagnosis of device thrombosis in continuous-flow left ventricular assist devices: the Columbia ramp study. J Am Coll Cardiol 2012;60:1764-75.

23. van den Brule JMD, van der Hoeven JG, Hoedemaekers CWE. Cerebral Perfusion and Cerebral Autoregulation after Cardiac Arrest. Biomed Res Int 2018;2018:4143636.

24. Lepic T, Loncar G, Bozic B, et al. Cerebral blood flow in the chronic heart failure patients. Perspect Med 2012;1:304-8.

25. Bhimaraj A, Uribe C, Suarez EE. Physiological impact of continuous flow on end-organ function: clinical implications in the current era of left ventricular assist devices. Methodist Debakey Cardiovasc J 2015;11:12-7.

26. Sundgreen C, Larsen FS, Herzog TM, et al. Autoregulation of cerebral blood flow in patients resuscitated from cardiac arrest. Stroke 2001;32:128-32.

27. Callaway CW, Donnino MW, Fink EL, et al. Part 8: Post-Cardiac Arrest Care: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2015;132:S465-82.

Appendix 1: Methods

Study variables and definitions

The primary diagnosis of RHF after LVAD implantation was made by the presence of at least two of the clinical evidences (i.e., ascites, peripheral edema, elevated estimated or measured CVP) or at least one of the manifestations (i.e., renal failure, liver injury, cardiac index <2.2 L/min/m^2, mixed venous oxygen saturation <50%, reduction in pump flow >30% from the previous baseline, or elevated lactate >3.0 mmol/L), consistent with INTERMACS definition. Other post-LVAD complications were also defined according to standard INTERMACS definitions.

Statistical analysis

Categorical variables were compared using chi-square or Fisher's exact tests; continuous variables were compared using two-sample *t*-tests or Wilcoxon rank-sum tests. All statistical testing was two-sided with an alpha level of 0.05.

A Fine and Gray competing risk model was used to calculate the cumulative incidence rate of stroke with a relative 95% standard error, considering death and heart transplantation as competing events. The cumulative incidence rate of death was calculated in a similar manner, considering heart transplantation as a competing event.

A Cox proportional hazard regression analysis was performed to identify predictors of early stroke at 6 months after implantation. Variables that were significant on univariable analyses or that were clinically relevant were included in the multivariable analyses. Preoperative frailty, stroke history, cardiac surgery history, preoperative CVP, device type, concomitant valve surgery, postoperative RHF, antiplatelet use, atrial fibrillation, mean MAP within 3 days of implantation, mean CPP within 3 days of implantation and at POD 0 and 1 were included in multivariable analysis. The backward elimination method was used for model selection in the multivariable analysis. Multivariable analyses for RHF and CPP were conducted separately, due to multicollinearity. Results are reported as HRs with 95% CIs.

ROC curve analysis for early stroke was performed, and the AUC was calculated. An AUC of 0.5 was considered no better than chance, whereas an AUC of 1 indicated a perfect accuracy. The optimal cutoff for predicting early stroke by CPP was determined using the maximum value of the Youden index, the sum of sensitivity, and a specificity of minus one.

Statistical analyses were performed using SPSS software version 25.0 (IBM Corp., Armonk, NY, USA) and R Statistical software version 4.0.2 (R Project for Statistical Computing, Vienna, Austria).

Table S1 Previous cardiac surgery history

Variables	No stroke group (n=56)	Stroke group (n=14)	P value
Valve surgery	3 (5.4)	3 (21.4)	0.090
Aortic valve surgery	1 (1.8)	1 (7.1)	
Mitral valve surgery	1 (1.8)	1 (7.1)	
Aortic valve and mitral valve surgery	0 (0.0)	1 (7.1)	
Mitral valve and tricuspid valve surgery	1 (1.8)	0 (0.0)	
Coronary artery bypass graft surgery	3 (5.4)	6 (42.9)	0.001
Totally thoracoscopic ablation	1 (1.8)	0 (0.0)	>0.99

Data are expressed as number (%).

**Figure S1** Serial changes in (A) CPP, (B) MAP, and (C) CVP according to stroke. The horizontal line in the middle of each box indicates the median; the top and bottom borders of the box mark the 75th and 25th percentiles, respectively; and the top and bottom ends of the line mark the 90th and 10th percentiles. CPP, cerebral perfusion pressure; MAP, mean arterial pressure; CVP, central venous pressure.

Figure S2 Serial changes in (A) pump flow, (B) pump flow index, (C) LDH, and (D) INR. The horizontal line in the middle of each box indicates the median; the top and bottom borders of the box mark the 75th and 25th percentiles, respectively; and the top and bottom ends of the line mark the 90th and 10th percentiles. LDH, lactate dehydrogenase; INR, international normalized ratio.

Figure S3 Time to event curves for death according to stroke. Cumulative incidence function was used. The colored shaded areas in both curves represent the 95% CI. CI, confidence interval.

Table S2 Univariable analysis for postoperative early stroke

| Variables	Univariable analysis		
	HR	95% CI	P value
Age (years)	0.990	0.955–1.027	0.598
Male sex	1.634	0.512–5.213	0.407
Body mass index (kg/m^2)	1.011	0.852-1.201	0.899
Preoperative comorbidity			
Frailty	7.994	1.045–61.135	0.045
DM	1.303	0.437-3.888	0.635
HTN	1.460	0.506-4.211	0.484
Chronic renal failure	1.242	0.431–3.580	0.689
Previous stroke history	2.190	0.733–6.540	0.160
Smoking history	1.258	0.436–3.626	0.671
Solid organ cancer	0.449	0.060–3.488	0.449
Atrial fibrillation	1.019	0.353–2.936	0.973
Cardiac surgery history	5.409	1.873–15.621	0.002
CPR history	0.819	0.274–2.785	0.819
ECMO status before LVAD implantation	1.588	0.551–4.580	0.392
Liver dysfunction	0.750	0.603–2.641	0.750
Ischemic etiology of heart failure	2.029	0.680–6.060	0.205
Preoperative ECHO			
LVEF			0.363
30–39%	1		
20–29%	1.572	0.393–6.291	
<20%	0.572	0.174–1.873	
TR			0.756
None	1		
Mild	1.245	0.129–11.971	
Moderate	0.787	0.209–2.971	
Severe	0.417	0.070–2.499	
Mean PAP (mmHg)	1.017	0.964–1.073	0.535
CVP (mmHg)	1.066	0.970–1.170	0.183
Operative			
Device type			0.157
HMII	1		
HVAD	7.373	0.964–56.391	
HM3	<0.001		
Concomitant valve surgery	0.247	0.032-1.886	0.178
Intracardiac thrombus removal	0.578	0.076–4.419	0.597
Postoperative			
RHF	5.050	1.686–15.129	0.004
Infection	0.516	0.115–2.306	0.386
Antiplatelet use	0.393	0.132–1.174	0.094
Heparin bridging	3.166	0.414–24.209	0.267
Atrial fibrillation	2.418	0.810–7.220	0.114
TTR using the Rosendaal method	0.593	0.208–1.691	0.328
Pump flow within 7 days of implantation	0.853	0.466–1.561	0.606
Mean MAP within 3 days of implantation	0.934	0.862–1.011	0.092
Mean CVP within 3 days of implantation	1.132	0.915–1.401	0.254
Mean CPP within 3 days of implantation	0.944	0.880–1.012	0.103
Mean CPP at POD 0	0.945	0.892–1.002	0.057
Mean CPP at POD 1	0.920	0.858–0.985	0.017
Mean CPP at POD 2	0.985	0.925–1.048	0.629
Mean CPP at POD 3	0.953	0.889–1.022	0.181

HR, hazard ratio; CI, confidence interval; DM, diabetes mellitus; HTN, hypertension; CPR, cardiopulmonary resuscitation; ECMO, extracorporeal membrane oxygenation; LVAD, left ventricular assist device; ECHO, echocardiography; LVEF, left ventricular ejection fraction; TR, tricuspid regurgitation; PAP, pulmonary arterial pressure; CVP, central venous pressure; HMII, HeartMate II Left Ventricular Assist System; HVAD, HeartWare Ventricular Assist Device System; HM3, HeartMate 3 Left Ventricular Assist System; TTR, time in therapeutic range; MAP, mean arterial pressure; CPP, cerebral perfusion pressure; POD, postoperative day; RHF, right heart failure.

Table S3 Multivariable analysis for postoperative early stroke

Variables	Multivariable analysis		
	HR	95% CI	P value
Preoperative			
Cardiac surgery history	3.916	1.323–11.594	0.014
Postoperative			
Antiplatelet use	0.286	0.093–0.881	0.029
CPP at POD 1	0.923	0.858–0.992	0.030

HR, hazard ratio; CI, confidence interval; CPP, cerebral perfusion pressure; POD, postoperative day.

Figure S4 Forest plot based on the results of multivariate analysis of the factors associated with early stroke. Note: The factors that were found to be significant (P<0.1) in univariate analysis and clinically relevant were entered into a multivariate Cox regression model.

Figure S5 ROC curve for prediction of stroke by CPP at POD 1. Optimal cutoff values using the Youden index were 62 mmHg. POD, postoperative day; AUC, area under the curve; ROC, receiver operating characteristic; CPP, cerebral perfusion pressure.

Table S4 Clinical characteristics and echocardiographic characteristics 6 months after implantation

Variables	No RHF group (n=48)	RHF group (n=22)	P value
Age (years)	65.94±12.04	56.68±15.71	0.009
Male sex	40 (83.3)	15 (68.2)	0.263
Body mass index (kg/m^2)	23.48±3.04	22.80±3.06	0.394
Preoperative comorbidity			
Frailty	30 (62.5)	15 (68.2)	0.848
DM	30 (62.5)	11 (50.0)	0.469
HTN	26 (54.2)	8 (36.4)	0.260
Dialysis	18 (37.5)	9 (40.9)	0.994
Previous stroke history	11 (22.9)	4 (18.2)	0.893
Smoking history	24 (50.0)	11 (50.0)	>0.99
Solid organ cancer	6 (12.5)	3 (13.6)	>0.99
Liver dysfunction	13 (27.1)	9 (40.9)	0.379
Atrial fibrillation	28 (58.3)	12 (54.5)	0.970
Cardiac surgery history	12 (25.0)	7 (31.8)	0.760
CPR history	15 (31.3)	7 (31.8)	>0.99
ECMO status before LVAD implantation	16 (33.3)	8 (36.4)	>0.99
Ischemic etiology of heart failure	26 (54.2)	9 (40.9)	0.440
Medical support status			0.022
Bridge to transplantation	23 (47.9)	15 (68.2)	
Bridge to candidacy	1 (2.1)	3 (13.6)	
Destination therapy	24 (50.0)	4 (18.2)	
Preoperative ECHO			
LVEF			0.621
30–39%	5 (10.4)	4 (18.2)	
20–29%	24 (50.0)	11 (50.0)	
<20%	19 (39.6)	7 (31.8)	
TR			0.306
Mild	31 (64.6)	9 (40.9)	
Moderate	9 (18.8)	7 (31.8)	
Severe	6 (12.5)	5 (22.7)	
Mean PAP (mmHg)	35.05±10.10	37.59±12.30	0.422
CVP (mmHg)	11.38±5.88	13.35±7.47	0.289

Data are expressed as number (%) or mean ± standard deviation. RHF, right heart failure; DM, diabetes mellitus; HTN, hypertension; CPR, cardiopulmonary resuscitation; ECMO, extracorporeal membrane oxygenation; LVAD, left ventricular assist device; ECHO, echocardiography; LVEF, left ventricular ejection fraction; TR, tricuspid regurgitation; PAP, pulmonary arterial pressure; CVP, central venous pressure.

Table S5 Surgical characteristics and postoperative characteristics at 6 months

Variables	No RHF group (n=48)	RHF group (n=22)	P value
Surgical characteristics			
Device type			0.029
HMII	20 (41.7)	3 (13.6)	
HM3	0 (0.0)	1 (4.5)	
HVAD	28 (58.3)	18 (81.8)	
Intracardiac thrombus removal	5 (10.4)	3 (13.6)	>0.99
Concomitant valve surgery	11 (22.9)	5 (22.7)	>0.99
Postoperative characteristics			
Time from LVAD implantation to RHF (days)	–	1 [0–6]	–
Postoperative early stroke	5 (10.4)	9 (40.9)	0.008
Time from LVAD implantation to stroke (days)	105 [1.29–180]	48 [12–180]	0.606
Time from RHF to stroke (days)	–	45 [11–147]	–
Antiplatelet use	40 (83.3)	16 (72.7)	0.479
Heparin bridging	39 (81.3)	18 (81.8)	>0.99
Postoperative atrial fibrillation	11 (22.9)	5 (22.7)	>0.99
Postoperative infection	15 (31.3)	2 (9.1)	0.088
Postoperative pump thrombosis	0 (0.0)	0 (0.0)	NA
Heparin induced thrombocytopenia	0 (0.0)	0 (0.0)	NA
TTR using Rosendaal method <40%	30 (62.5)	11 (50.0)	0.350
Pump flow within 7 days of implantation (L/min)	4.18±1.00	3.89±0.69	0.222
Mean MAP within 3 days of implantation (mmHg)	73.97±10.69	69.20±10.72	<0.001
Mean CVP within 3 days of implantation (mmHg)	9.85±3.70	11.82±4.39	<0.001
Mean CPP within 3 days of implantation (mmHg)	64.13±10.56	57.38±11.55	<0.001
Mean CPP at POD 0 (mmHg)	63.66±12.29	54.61±11.00	<0.001
Mean CPP at POD 1 (mmHg)	63.10±10.09	57.69±11.15	<0.001
Mean CPP at POD 2 (mmHg)	65.75±9.49	60.33±12.64	<0.001
Mean CPP at POD 3 (mmHg)	73.138±12.44	67.37±12.69	<0.001

Data are expressed as number (%), mean ± SD, or median [range]. RHF, right heart failure; HMII, HeartMate II Left Ventricular Assist System; HM3, HeartMate 3 Left Ventricular Assist System; HVAD, HeartWare Ventricular Assist Device System; LVAD, left ventricular assist device; NA, not available; TTR, time in therapeutic range; MAP, mean arterial pressure; CVP, central venous pressure; CPP, cerebral perfusion pressure; POD, postoperative day.

Table S6 Management of patients with postoperative RHF

Variables	Postoperative RHF (n=22)
In hospital	
Inotropes[†]	
Number (%)	22 (100.0)
Duration (days), median [range]	7 [2–44]
Inhaled NO	
Number (%)	9 (40.9)
Duration (days), median [range]	2 [1–7]
CRRT	
Number (%)	15 (68.2)
Duration (days), median [range]	7.5 [1–23]
RVAD implantation	
Number (%)	4 (18.2)
Duration (days), median [range]	8.5 [5–12]
At discharge, n (%)	
Sildenafil	15 (68.2)
Digoxin	8 (36.4)
High dose diuretics[‡]	4 (18.2)
6 months after LVAD implantation, n (%)	
Sildenafil	10 (45.5)
Digoxin	3 (13.6)
High dose diuretics[‡]	4 (18.2)
Duration between RHF onset and stroke, median [range]	45 [11–147]

[†], inotropes included intravenous medications such as dobutamine and milrinone; [‡], high dose diuretics were defined as furosemide at a daily oral dosage of 80 mg or more, or torasemide at a daily oral dosage of 20 mg or more. RHF, right heart failure; NO, nitric oxide; CRRT, continuous renal replacement therapy; RVAD, right ventricular assist device; LVAD, left ventricular assist device.